Effect of intravenous pentoxifylline in inflammatory response in patients undergoing nephrolithotomy

Journal of Endourology

Volumn 23, Issue 2, 2009, Pages 323-328

  Izadpanah, Fatemeh ^a   Mojtahedzadeh, Mojtaba ^a   Aghamir, Seyed Mohammad Kazem ^a   Atharikia, Davood ^a   Dashti, Simin ^a   Abbasi, Ali ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; MORPHINE; NARCOTIC AGENT; PENTOXIFYLLINE; PETHIDINE; PLACEBO; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANALGESIA; ANESTHESIST; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENERAL ANESTHESIA; HOSPITALIZATION; HUMAN; INFLAMMATION; LABORATORY TEST; MALE; MEDICAL SOCIETY; NAUSEA AND VOMITING; NEPHROLITHOTOMY; OPERATION DURATION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VENOUS BLOOD; VERBAL RATING SCALE; VISUAL ANALOG SCALE;

ADULT; BLOOD CELL COUNT; C-REACTIVE PROTEIN; CREATININE; DEMOGRAPHY; FEMALE; HUMANS; INFLAMMATION; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEPHROSTOMY, PERCUTANEOUS; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 60349086089     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2008.0474     Document Type: Article

References (34)

1. Ward A, Clissold SP. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97.
2. Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate exaggerated pain states: Implications for clinical pain. Adv Exp Med Biol 2003;521:1-21.
3. Wordliczek J, Szczepanik AM, Banach M, et al. The effect of pentoxifiline on post-injury hyperalgesia in rats and postoperative pain in patients. Life Sci 2000;66:1155-1164.
4. Wan S, LeClerc JL, Vincent JL. Cytokine responses to cardiopulmonary bypass: Lessons learned from cardiac transplantation. Ann Thorac Surg 1997;63:269-276.
5. de Mendonca-Filho HT, Pereira KC, Fontes M, Vieira DA, de Mendonca ML, Campos LA, Castro-Faria-Neto HC. Circulating inflammatory mediators and organ dysfunction after cardiovascular surgery with cardiopulmonary bypass: A prospective observational study. Crit Care 2006;10:R46.
6. Faist E, Schinkel C, Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg 1996;20:454-459.
7. Romeo C, Cruccetti A, Turiaco A, et al. Monocyte and neutrophil activity after minor surgical stress. J Pediatr Surg 2002;37:741-744.
8. Sheeran P, Hall GM. Cytokines in anaesthesia. Br J Anaesth 1997;78:201-219.
9. Hensler T, Hecker H, Heeg K, et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 1997;65:2283-2291.
10. Roumen RM, Hendriks T, van der Ven-Jongekrijg J, Nieuwenhuijzen GA, Sauerwein RW, van der Meer JW, Goris RJ. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993;218:769-776.
11. Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. Systemic cytokine response after major surgery. Br J Surg 1992;79:757-760.
12. Desborough JP. The stress response to trauma and surgery. Br J Anaesth 2000;85:109-117.
13. Biffl WL, Moore EE, Moore FA, Peterson VM. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg 1996;224:647-664.
14. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101:311-320.
15. Hoffmann H, Markewitz A, Kreuzer E, Reichert K, Jochum M, Faist E. Pentoxifylline decreases the incidence of multiple organ failure in patients after major cardio-thoracic surgery. Shock 1998;9:235-240.
16. Ustunsoy H, Sivrikoz MC, Tarakcioglu M, Bakir K, Guldur E, Celkan MA. The effects of pentoxifylline on the myocardial inflammation and ischemia-reperfusion injury during cardiopulmonary bypass. J Card Surg 2006;21:57-61.
17. Türköz R, Yörükoglu K, Akcay A, Yilik L, Baltalarli A, Karahan N, Adanir T, Sagban M. The effect of pentoxifylline on the lung during cardiopulmonary bypass. Eur J Cardiothorac Surg 1996;10:339-346.
18. Boldt J, Brosch C, Lehmann A, Haisch G, Lang J, Isgro F. Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients. Ann Thorac Surg 2001;71: 1524-1529.
19. Cagli K, Ulas MM, Ozisik K, et al. The intraoperative effect of pentoxifylline on the inflammatory process and leukocytes in cardiac surgery patients undergoing cardiopulmonary bypass. Perfusion 2005;20:45-51.
20. Lu CH, Chao PC, Borel CO, Yang CP, Yeh CC, Wong CS, Wu CT. Preincisional intravenous pentoxifylline attenuating perioperative cytokine response, reducing morphine consumption, and improving recovery of bowel function in patients undergoing colorectal cancer surgery. Anesth Analg 2004;99:1465-1471.
21. Brannen GE, Bush WH, Correa RJ, Gibbons RP, Elder JS. Kidney stone removal: Percutaneous versus surgical lithotomy. J Urol 1985;133:6-12.
22. Brown MW, Carson CC III, Dunnick NR, Weinerth JL. Comparison of the costs and morbidity of percutaneous and open flank procedures. J Urol 1986;135:1150-1152.
23. Silverstein AD, Terranova SA, Auge BK, et al. Bilateral renal calculi: Assessment of staged v synchronous percutaneous nephrolithotomy. J Endourol 2004;18:145-151.
24. Mojtahedzadeh M, Izadpanah F, Kazem Aghamir SM, Atharikia D, Reza Nikoobahkt M, Abbasi A. Effect of intravenous pentoxifylline on oxidative stress in patients undergoing nephrolithotomy. Minerva Urol Nefrol 2008;60:151-157.
25. Clauss A. [Rapid physiological coagulation method for the determination of fibrinogen.] (Ger) Acta Haematol 1957;17:237-246.
26. Heinze H, Rosemann C, Weber C, Heinrichs G, Bahlmann L, Misfeld M, Heringlake M, Eichler W. A single prophylactic dose of pentoxifylline reduces high dependency unit time in cardiac surgery - a prospective randomized and controlled study. Eur J Cardiothorac Surg 2007;32:83-89.
27. Holzheimer RG, Steinmetz W. Local and systemic concentrations of pro- and anti-inflammatory cytokines in human wounds. Eur J Med Res 2000;5:347-355.
28. Cruickshank AM, Fraser WD, Burns HJ, Van Damme J, Shenkin A. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci (Lond) 1990;79:161-165.
29. Naito Y, Tamai S, Shingu K, Shindo K, Matsui T, Segawa H, Nakai Y, Mori K. Responses of plasma adrenocorticotropic hormone, cortisol, and cytokines during and after upper abdominal surgery. Anesthesiology 1992;77:426-431.
30. Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989;143:3517-3523.
31. Sachs D, Cunha FQ, Poole S, Ferreira SH. Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain 2002;96:89-97.
32. Koo DJ, Yoo P, Cioffi WG, Bland KI, Chaudry IH, Wang P. Mechanism of the beneficial effects of pentoxifylline during sepsis: Maintenance of adrenomedullin responsiveness and downregulation of proinflammatory cytokines. J Surg Res 2000;91:70-76.
33. Schubert P, Ogata T, Marchini C, Ferroni S, Rudolphi K. Protective mechanisms of adenosine in neurons and glial cells. Ann N Y Acad Sci 1997;825:1-10.
34. Hemmer CJ, Hort G, Chiwakata CB, et al. Supportive pentoxifylline in falciparum malaria: no effect on tumor necrosis factor alpha levels or clinical outcome: A prospective, randomized, placebo-controlled study. Am J Trop Med Hyg 1997;56:397-403.